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Abstract
Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an
intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50
years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with
previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major
cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of
hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-
based intervention to prevent the incidence of hypertension and the development of target-organ damage.
Methods: This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years,
with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo.
The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of
microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal
cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and
sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of
hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625
participants per group. The project was approved by the Ethics committee of each participating institution.
Discussion: The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main
mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of
hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-
based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil.
Trial Registration: Clinical Trials NCT00970931.
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High blood pressure is the major risk factor for cardio-
vascular disease. The risks start at blood pressure values
as lower as 115/75 mmHg, but increase exponentially
and confer increased absolute risks with blood pressure
higher than 140/90 mmHg [1,2]. Cardiovascular disease
is already the leading cause of death in Brazil. The pre-
valence of hypertension in Brazil ranges from 22.3 to
44% of adults [3]. Therefore, interventions aiming to
prevent or treat high blood pressure are highly needed.
The rationale for precocious drug intervention to pre-
vent hypertension was recently presented [4] and is
summarized below.
Thresholds of risk for blood pressure
A meta-analysis of 61 cohort studies, with more than one
million of subjects (12.7 million persons-year at risk), pre-
senting more than 56,000 fatal cardiovascular events,
demonstrated that the risk for cardiovascular events starts
with systolic blood pressure higher than 115 mmHg or
diastolic blood pressure higher than 75 mmHg, doubling
at each 20 mmHg in the first case or 10 mmHg in the
second [1]. The risks of pre-hypertension and high normal
blood pressure have been confirmed in other cohorts [5,6].
The efficacy of blood pressure-lowering drugs to reduce
such risks, with a magnitude anticipated by the cohort
studies, corroborated in the experimental setting the
estimation of risks [7].
Physiopathological basis for early intervention
The raising of blood pressure with age is not inexor-
able and does not occur in populations that do not
consume large amounts of salt. Under the contempor-
ary and unnatural overload of dietary sodium, kidneys
had to reset their primary sodium handling function
from retention to excretion. Subjects with familial pre-
disposition to hypertension require higher renal flow
and consequently higher blood pressure to eliminate
the sodium overload, resulting in extracellular volume
expansion, increase in cardiac output and peripheral
resistance. With long-standing high blood pressure,
loss of glomeruli and renal arterioles may further shift
pressure natriuresis and exacerbate blood pressure ele-
vation. The recurrence of this phenomenon along the
years leads to arteriolar hypertrophy and sustained
blood pressure rise [8-11]. After a long period of high
peripheral resistance and diastolic blood pressure, stiff-
ness of large vessels arises, with consequent rise of sys-
tolic blood pressure. This deleterious natural history of
blood pressure rising with ageing could be aborted in
t h ev e r yb e g i n n i n gb yal o w - s a l td i e to rb yi n c r e a s i n g
natriuresis, which could be accomplished by very low
doses of diuretics or other drugs that enhance the
renal capacity of excreting sodium.
Incidence of hypertension in patients with pre-
hypertension
The worldwide prevalence of hypertension in individuals
older than 70 years was 70% of women and 59% of men
[12]. The incidence of hypertension increases with age
until the fifth decade, particularly among individuals
with high-normal blood pressure [13]. Four out of five
individuals with pre-hypertension aged 40 to 49 years
developed hypertension in 10 years in a population-
based cohort study conducted in Porto Alegre, Brazil
[14]. Therefore, pre-hypertension is not only a risk by
itself but it identifies individuals at higher risk for the
development of full hypertension in a short period of
time.
Low effectiveness of non-drug interventions in patients
with hypertension and pre-hypertension
The risk factors for hypertension, such as the excessive
dietary sodium intake, low potassium consumption,
excess of adiposity, insulin resistance, abuse of alcoholic
beverages, and low consumption of fruits and vegetables
are well-known. Many nutritional and behavioral inter-
ventions are efficacious to reduce blood pressure, but
outside the strict experimental conditions their effective-
ness has been inconsistent. The mean weight of popula-
tions is not stable but has increased in recent years
worldwide. Randomized controlled trials with long fol-
low-up periods have shown that the efficacy of weight
control interventions is lost with time. In the TOHP-II
trial, weight, salt consumption and blood pressure
returned to the baseline values after 36 months of inter-
vention [15]. The DASH diet, which was highly effica-
cious in a strictly controlled trial [16], was only
marginally efficacious in the PREMIER study [17], where
differences in blood pressure emerged only when com-
pared with the advice group. The efficacy of low-salt
diets was negligible in trials that lasted more than six
months [18]. In a clinical context, only the recommen-
dation to lose weight had a short-term effect on blood
pressure [19].
The efficacy of drugs to prevent hypertension in patients
with pre-hypertension
Two large clinical trials showed that the prevention of
hypertension by drug treatment is feasible and well tol-
erated. In the TROPHY study [20], 772 individuals with
systolic blood pressure between 130 and 139 mmHg or
diastolic blood pressure between 85 and 89 mmHg were
randomized to candesartan, 16 mg daily or placebo,
beside recommendations to change lifestyle. After two
years, the incidence of hypertension was 66% lower in
individuals treated with candesartan (relative risk 0.34,
95% CI: 0.25-0.44), corresponding to a NNT of 4, which
means that four individuals should be treated to prevent
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was interrupted and blood pressure tended to return to
the levels of the control group. The treatment was well
tolerated. Similar but not so intense efficacy was
observed in the study PHARAO [21], which compared
ramipril with placebo.
Prevention of cardiovascular events in patients with
blood pressure within normal values
The expectation that BP agents have beneficial effects
independent of the blood pressure-lowering one (pleio-
tropic effects) is still deep-rooted in physician’sm i n d s ,
but it has been repeatedly dismissed by independent
clinical trials and by a large meta-analysis [7] The effi-
cacy of beta-blockers in patients recovering from a myo-
cardial infarction and in patients with heart failure, of
ACE inhibitors in patients with heart failure, coronary
heart disease, other evidences of atherosclerotic vascular
disease or diabetes, and patients recovered from a stroke
(with a diuretic) can be almost fully explained by the
blood pressure-lowering effect [22]. At least part of the
evidences supporting the existence of such effects may
have resulted from biases in the planning and interpre-
tation of clinical trials funded by pharmaceutical compa-
nies [23].
Trial rationale
The early use of blood pressure-lowering drugs may
prevent cardiovascular events and the incidence of
hypertension. The very low absolute risk of pre-hyper-
tension in young individuals free of diabetes or cardio-
vascular disease precludes the launching of clinical trials
with the aim to prevent hard outcomes. The blood pres-
sure-lowering effect and the prevention of the incidence
of full hypertension may be valid surrogate endpoints
that could be investigated in feasible randomized clinical
trials. The PREVER prevention trial study will test if a
low dose of an association of chlorthalidone with
amiloride prevents hypertension at an acceptable safety
in a nationwide large sample of individuals with pre-
hypertension (Clinical trials registration number:
NCT00970931). Other intermediate outcomes, such as
microalbuminuria and left ventricular hypertrophy, are
going to be investigated. Diuretics were chosen in face
of their cost-effectiveness, since they are at least as effi-
cacious as other blood pressure agents [24], at very low
frequency of adverse effects, and the fact that they are
the cheapest agents. Chlorthalidone was chosen in face
of its higher blood pressure-lowering efficacy and better
performance in the prevention of major cardiovascular
events than hydrochlorothiazide [24]. The association
with amiloride aims to prevent the deleterious hypokale-
mia induced by diuretics [25,26]. If the intervention
shows to be effective and well-tolerated, the early use of
this association could be the basis for an innovative
public health program to prevent hypertension in Brazil.
Research questions
1. Does an association of low doses of chlorthalidone
and amiloride reduce the incidence of hypertension in
individuals with pre-hypertension?
2. Does an association of low doses of chlorthalidone
and amiloride reduce the incidence of target-organ
damage in patients with pre-hypertension?
3. Does an association of low doses of chlorthalidone
and amiloride reduce the incidence of cardiovascular
events in patients with pre-hypertension?
4. Is the association of low doses of chlorthalidone
and amiloride safe to be used on a population-based
perspective?
Methods
Design
randomized, double-blind, clinical trial, controlled by
placebo.
Eligible participants
individuals with 30 to 70 years of age with pre-
hypertension.
Exclusion criteria
low life expectancy, other indications for the use of
diuretics, such as cardiovascular disease, intolerance to
the study drugs, pregnancy.
Random allocation
will be generated by a computer, using a validated soft-
ware (Random allocator), with variable block sizes and
stratified by center.
Interventions
Chlorthalidone 12.5 mg plus amiloride 2.5 mg or identi-
cal placebo. Figure 1 shows flow-chart of selection of
participants and interventions.
Outcomes
Primary:
1. Incidence of hypertension.
2. Adverse events.
3. Development or worsening of microalbuminuria
and of left ventricular hypertrophy in the EKG.
Secondary: fatal or non-fatal cardiovascular events.
Follow-up and duration of the study
consultations for evaluation and enrollment and there-
after consultations at the third, 6
th,9
th,1 2
th and 18
th
months. Figure 2 shows the summary of key practical
aspects of the trial. Lifestyle interventions will be applied
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throughout the trial. An extended follow-up is planned
pending on additional funding.
Assessment of outcomes
Incidence of hypertension: the diagnosis of hypertension
will be signaled at any of the follow-up visits by average
b l o o dp r e s s u r e( t w om e a s u r e m e n t sb ya na u t o m a t i c
electronic device Microlife BP 3BTO-A, licensed for
fabrication by Micromed Biotecnologia Ltda, Brasília,
Brazil) ≥ 140/90 mmHg. The diagnosis will be confirmed
by a new visit soon afterwards, with the average of blood
pressure measurements of both consultations within
hypertensive levels.
Adverse events: adverse events will be investigated by
open questions and by a semi-structured questionnaire
including general symptoms and the presumed adverse
effects of the drugs used in the trial. The incidence of
Consent form
Males/ Females, 30 - 70 years old
POTENTIALLY ELIGIBLE (Time 0)
Males/ Females, 30  70 years old
Office average blood pressure: 120-139/80-89 mmHg
If diabetes mellitus: Systolic BP:120-130 mmHg
LIFESTYLE MODIFICATION (Months 1 to 3)
Weight control
Dash diet like
Low sodium 
Stop smoking
()
pg
Physical activity
Consent form
RANDOMIZATION (Month 3)
Prehypertension at office blood pressure
Blood tests
Urine analysis
ECG
Re-assessment
Office blood pressure
FOLLOW-UP VISITS (Months 6 to 15) 
p
Side-effects
Hypertension
OUTCOMES (Month 18) 
yp
Adverse events
Target-organ damage
Cardiovascular disease
Figure 1 Flow chart of the PREVER-prevention trial, describing selection, randomization and follow-up process.
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adverse events more frequent in the drug arm than in
the placebo arm. Laboratory adverse events, such as
hypokalemia, hyperuricemia and diabetes (glycated
hemoglobin and fasting glucose) will be investigated at
the final visit of the participants.
Target-organ damage: Microalbuminuria will be deter-
mined by nephelometry. Left ventricular hypertrophy
will be investigated by electrocardiogram, using the
Sokolow-Lyon voltage and the Cornell voltage-duration
product. These examinations will be carried out at the
baseline evaluation and the final visit.
Cardiovascular outcomes: from a statistical point of
view they will be secondary events, in face of the sample
power calculated for the trial. Figure 3 presents the
main outcomes that will be investigated. The cases will
be adjudicated on the basis of interview, hospital charts
and exams, death certificates and verbal autopsy with
next-of-kin, by members of the outcome committee.
Sample size calculation
assuming an incidence of hypertension of 14% in two
years in the control group, a size effect of 40% of reduc-
tion in the incidence in the treated group, for a power
of 85% and P alpha of 5%, it will be necessary to study
568 individuals per group, rounded to 625 per group to
compensate for losses in follow-up.
Statistics
the cumulative incidence of hypertension and adverse
events will be tested by Chi-square. Survival curves
(Kaplan Meyer) will be compared by log-rank test, and
Males or females, 30 to 70 years-old, prehypertension  (office 
blood pressure); no antihypertensive treatment, without 
allergy to chlortalidone and amiloride, and no previous CHD, allergy to chlortalidone  and amiloride, and no previous CHD, 
severe chronic disease, or pregnant women
Lifestyle
modification
Prehypertension
R Chlortalidone
and Amiloride Placebo
3 m
6m
3 m
6m 6 m
9 m
12 m
6 m
9 m
12 m 12 m
15 m
12 m
15 m
Hypertension
Adverse effects
Target-organ damage
Hypertension
Adverse effects
Target-organ damage
Figure 2 Summary of the PREVER-Prevention trial key practical aspects.
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compared by ANOVA for multiple repeated measure-
ments and factors, testing for the time-group interaction.
Logistics
this is a nation-based trial, with 24 clinical centers dis-
tributed in nine States. A Coordinating Committee was
responsible for the elaboration of this proposal and for
the main decisions regarding the trial. The organiza-
tional study chart will include an executive Committee,
a safety committee, outcome committee, data, lab and
EKG centers, and the research units
Discussion
The early use of blood pressure-lowering drugs in indivi-
duals with pre-hypertension may prevent cardiovascular
events, target-organ damage and the incidence of full
hypertension. Non-drug treatment (life-style changing) has
had low long-term effectiveness and blood pressure drugs
can circumvent such limitation. Diuretics may be particu-
larly efficacious in this regard, since they act on the main
mechanism of blood pressure rising with ageing. The asso-
ciation of chlorthalidone with amiloride combines the effi-
cacy of chlorthalidone with the potassium-sparing effect of
amiloride, preventing electrolyte and metabolic abnormal-
ities induced by chlorthalidone. If this association shows
to be effective and well-tolerated on a population-based
perspective, it could be the basis for an innovative public
health program to prevent hypertension in Brazil.
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